AbbVie terminates late-stage lung cancer trial
Aug 29 (Reuters) - AbbVie Inc ABBV.N on Thursday said it will discontinue the late-stage trial testing its experimental treatment for a type of lung cancer after it failed to show a survival benefit compared to placebo.
An independent data monitoring committee recommended terminating the trial after an interim analysis of data from the trial testing its treatment, Rova-T, as first-line therapy, the company said.
AbbVie last year halted enrollment in a trial testing Rova-T as a second-line therapy in lung cancer.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
((email@example.com; within the U.S. +1 646 223 8780, outside the U.S. +91 80 6749 1692;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Latest Markets Videos
- Native Americans sue Trump administration over Arizona copper project
- Trump administration shelves planned investment ban on Alibaba, Tencent, Baidu -sources
- U.S. asks Tesla to recall 158,000 vehicles for touchscreen failures
- J&J COVID-19 vaccine on track for March rollout, still aims for 1 bln doses this year -exec